{"id":"W2902672529","doi":"10.1200/jco.18.01624","title":"Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":235,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal; Centre hospitalier de l'Université Laval; Institute of Cancer Research; Jewish General Hospital","funders":"Daiichi Sankyo Europe; Genentech; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Public Health Agency; MacroGenics; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Genomic Health","keywords":"Letrozole; Palbociclib; Medicine; Breast cancer; Estrogen receptor; Internal medicine; Oncology; Urology; Cancer; Metastatic breast cancer; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001984237,0.002026448,0.002933182,0.0005970351,0.0004623765,0.001400016,0.001316914,0.001820534,0.01144455],"category_scores_gemma":[0.001812961,0.0008500046,0.001347629,0.000487703,0.001240224,0.001355625,0.000564544,0.004201346,0.001692513],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001327173,"about_ca_system_score_gemma":0.002212772,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009272542,"about_ca_topic_score_gemma":0.002874025,"domain_scores_codex":[0.9994554,0.0002935182,0.0000254073,0.000103751,0.00005237377,0.00006951373],"domain_scores_gemma":[0.9990873,0.0001839766,0.0001822735,0.00008087413,0.00005782912,0.0004076553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9737333,0.00859133,0.0004930145,0.0003238091,0.000481313,0.0000534819,0.00002513675,0.0004745078,0.002729421,0.0001732766,0.001864656,0.01105678],"study_design_scores_gemma":[0.9609198,0.03676687,0.0005578153,0.00001502399,0.0001484852,0.00003675592,0.000009317945,0.0003041406,0.0002260022,0.0001314687,0.0008755441,0.000008789645],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9642517,0.005903699,0.00142117,0.002915974,0.00142048,0.0106705,0.005038365,0.0004066517,0.007971559],"genre_scores_gemma":[0.9499713,0.004054969,0.004121014,0.004422651,0.000888417,0.01282635,0.008493952,0.00009085424,0.01513057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01144455,"threshold_uncertainty_score":0.03828591,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1484660686979292,"score_gpt":0.5541645440786152,"score_spread":0.405698475380686,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}